ACTRN12607000347460: A Phase III Study Comparing Low Dose Cyclosporine, Methotrexate And Prednisone Versus Standard Dose Cyclosporine and Methotrexate As Graft Versus Host Disease Prophylaxis In Myeloblative Allogeneic Stem Cell Transplantation (ALLG BM10 trial).
(Incorporating an Open-Label Sub-study Investigating The Use Of Valganciclovir In The Prevention Of Cytomegalovirus Infection In Hematopoietic Stem Cell Transplant Recipients (ML20712)) |
|
|
| Withdrawn | 3 | 300 | | | Australasian Leukaemia and Lymphoma Group, Commonwealth Department of Health and Ageing, St Vincent’s Hospital, Roche Australia | Graft Versus Host Disease , Prophylaxis In Myeloblative , Allogeneic Stem Cell , Transplantation, Prevention Of Cytomegalovirus , Infection In Hematopoietic Stem , Cell Transplant Recipients | | | | |
NCT00003414: Graft-Versus-Host Disease in Treating Patients With Recurrent or Refractory Lymphoma or Hodgkin's Disease |
|
|
| Completed | 3 | 50 | US | aldesleukin, recombinant interferon gamma, busulfan, cyclophosphamide, cyclosporine, peripheral blood stem cell transplantation, radiation therapy | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, National Cancer Institute (NCI) | Graft Versus Host Disease, Lymphoma | 05/04 | 05/04 | | |
2011-000088-28: A Randomized Phase III Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute GVHD after Unrelated Donor Hematopoietic Cell Transplantation using Nonmyeloablative Conditioning for Patients with Hematologic Malignancies A Multi-Center Trial |
|
|
| Ongoing | 3 | 300 | Europe | Sirolimus, Mycophenolatmofetil, Cyclosporine, EU/1/01/171/007, EU/1/01/171/001, EU/1/96/005/001, EU/1/96/005/004, EU/1/96/005/005, Coated tablet, Oral liquid, Capsule, Tablet, Powder for concentrate for solution for infusion, Capsule, soft, Oral suspension, Concentrate and solvent for concentrate for solution for infusion, Rapamune, CellCept, Sandimmun | Fred Hutchinson Cancer Research Center | Graft versus host disease, Graft versus host disease is a process where donor cells may react against cells of your body causing inflammation that can involve the skin, liver and gastrointestinal system., Not possible to specify | | | | |
